We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Serum DCAMKL1 Pre and Post Treatment in Patients With Pancreatic Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01580241
Recruitment Status : Active, not recruiting
First Posted : April 18, 2012
Last Update Posted : August 22, 2017
Information provided by (Responsible Party):

Study Description
Brief Summary:
The investigators believe DCAMKL-1 is a stem cell tumor marker and is elevated in patients with pancreatic cancer. The investigators would like to analyze its expression pre and post treatment, to gauge the correlation between current pancreatic cancer therapies and the expression of DCAMKL-1

Condition or disease
Pancreatic Cancer

Study Design

Study Type : Observational
Estimated Enrollment : 60 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Expression Patterns of Stem Cell Marker Doublecortin and CaM Kinase-Like-1 (DCAMKL-1) in Human Pancreatic Adenocarcinoma
Study Start Date : October 2010
Primary Completion Date : July 2015
Estimated Study Completion Date : December 2018

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Groups and Cohorts

Surgery group
Patients with pancreatic cancer who undergo surgical treatment only
Chemotherapy group
Patients with pancreatic cancer who undergo chemotherapy treatment only
Neoadjuvant group
Patients with pancreatic cancer who undergo neoadjuvant chemotherapy and surgery
Adjuvant group
Patients with pancreatic cancer who undergo surgery followed by chemotherapy

Outcome Measures

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Human patients with pancreatic cancer undergo various treatments for pancreatic cancer. We will examine the expression of Dcamkl-1 pre and post therapy (including, chemotherapy only, surgery only, neoadjuvant and adjuvant therapies) to correlate treatment with a change in DCAMKl-1 expression.

Inclusion Criteria:

  • pancreatic cancer

Exclusion Criteria:

  • age < 18, history of other types of cancer
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01580241

United States, Oklahoma
Stephensen Cancer Center
Oklahoma City, Oklahoma, United States, 73104
Sponsors and Collaborators
University of Oklahoma
Principal Investigator: Courtney Houchen, MD University of Oklahoma
More Information

Responsible Party: University of Oklahoma
ClinicalTrials.gov Identifier: NCT01580241     History of Changes
Other Study ID Numbers: 2606
First Posted: April 18, 2012    Key Record Dates
Last Update Posted: August 22, 2017
Last Verified: August 2017

Additional relevant MeSH terms:
Pancreatic Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases